The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2019 | Incorporating checkpoint-inhibitors into second-line CLL therapy
Alison Moskowitz
• 2 Jun 2019
Alison Moskowitz, MD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the incorporation of checkpoint-inhibitors into second-line CLL therapy and how the community can determine the best treatment options for patients. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
